中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 39 Issue 4
Apr.  2023
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2023  >  39(4): 810-817

Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2023.04.011
  • 1.

    Department of Gastroenterology, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China

  • 2.

    School of Clinical Medicine, Ningxia Medical University, Yinchuan 750000, China

Research funding:

National Natural Science Foundation of China (Youth Foundation) (81500454);

Science and Technology Program of Gansu Province (21JR7RA017);

Gansu Provincial Clinical Research Center for Severe Disease of Digestive System (20JR10RA107)

More Information
  • Corresponding author: YU Xiaohui, yuxiaohui528@126.com (ORCID: 0000-0002-8633-3281); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)
  • Received Date: 2022-09-07
  • Accepted Date: 2022-10-09
  • Published Date: 2023-04-20
    Abstract
  •   Objective  To investigate the expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its correlation with clinical indicators.  Methods  A total of 20 patients with chronic hepatitis B (CHB), 68 patients with hepatitis B cirrhosis, and 20 healthy controls who attended The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army from October 2020 to November 2021 were enrolled. According to Child-Pugh class, the patients with hepatitis B cirrhosis were divided into Child-Pugh class A group with 24 patients, Child-Pugh class B group with 24 patients, and Child-Pugh class C group with 20 patients. After peripheral blood samples were collected to isolate serum and peripheral blood mononuclear cells (PBMCs), flow cytometry was used to measure the expression of membrane-bound Sema4D (mSema4D)+CD4+ T cells and mSema4D+CD8+ T cells in PBMCs, and ELISA was used to measure the expression of soluble Sema4D (sSema4D) in serum; their correlation with viral replication and liver inflammation markers was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Mann-Whitney U test was used for further comparison between two groups; a Spearman correlation analysis was also performed.  Results  There were significant differences in the expression of mSema4D+CD4+ T cells and mSema4D+CD8+ T cells between the CHB group, the hepatitis B cirrhosis group, and the control group (F=43.092 and 13.344, both P < 0.001), while there were significant differences between any two groups (P < 0.05). The expression levels of mSema4D+CD4+ T cells and mSema4D+CD8+ T cells gradually decreased with increasing Child-Pugh class (F=14.093 and 17.154, both P < 0.05), and there were significant differences between any two groups (P < 0.05). The content of sSema4D was 1.54(1.42-1.71) ng/mL in the control group, 1.08(1.07-1.38) ng/mL in the CHB group, and 4.87(2.13-14.97) ng/mL in the hepatitis B cirrhosis group, with a significant difference between the three groups (H=32.366, P < 0.001) and between any two groups (P < 0.05). The content of sSema4D was 2.42(0.59-5.65) ng/mL in the Child-Pugh class A group, 4.92(2.75-12.73) ng/mL in the Child-Pugh class B group, and 14.18(4.59-18.43) ng/mL in the Child-Pugh class C group, with a significant difference between the three groups (H=11.889, P=0.003) and between any two groups (P < 0.05). In patients with hepatitis B cirrhosis, the level of sSema4D was positively correlated with the levels of alanine aminotransferase (ALT) and HBV DNA quantification (r=0.294 and 0.430, both P < 0.05).  Conclusion  Sema4D is lowly expressed on T cell membrane and highly expressed in serum of patients with hepatitis B cirrhosis, and sSema4D may be involved in the development and progression of hepatitis B cirrhosis by affecting the levels of ALT and HBV DNA.

     

    • FullText(HTML)
  • loading
    • References(34)
  • [1]
    SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
    [2]
    SHI W, KUMANOGOH A, WATANABE C, et al. The class Ⅳ semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice[J]. Immunity, 2000, 13(5): 633-642. DOI: 10.1016/s1074-7613(00)00063-7.
    [3]
    DELAIRE S, BILLARD C, TORDJMAN R, et al. Biological activity of soluble CD100. Ⅱ. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration[J]. J Immunol, 2001, 166(7): 4348-4354. DOI: 10.4049/jimmunol.166.7.4348.
    [4]
    ELHABAZI A, DELAIRE S, BENSUSSAN A, et al. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis[J]. J Immunol, 2001, 166(7): 4341-4347. DOI: 10.4049/jimmunol.166.7.4341.
    [5]
    LIU B, MA Y, ZHANG Y, et al. CD8low CD100- T cells identify a novel CD8 T cell subset associated with viral control during human hantaan virus infection[J]. J Virol, 2015, 89(23): 11834-11844. DOI: 10.1128/JVI.01610-15.
    [6]
    YOSHIDA Y, OGATA A, KANG S, et al. Semaphorin 4D contributes to rheumatoid arthritis by inducing inflammatory cytokine production: pathogenic and therapeutic implications[J]. Arthritis Rheumatol, 2015, 67(6): 1481-1490. DOI: 10.1002/art.39086.
    [7]
    ZHANG C, QIAO H, GUO W, et al. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis[J]. Cancer Lett, 2019, 455: 1-13. DOI: 10.1016/j.canlet.2019.04.013.
    [8]
    Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.

    中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
    [9]
    BASILE JR, HOLMBECK K, BUGGE TH, et al. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D[J]. J Biol Chem, 2007, 282(9): 6899-6905. DOI: 10.1074/jbc.M609570200.
    [10]
    KUMANOGOH A, WATANABE C, LEE I, et al. Identification of CD72 as a lymphocyte receptor for the class Ⅳ semaphorin CD100: a novel mechanism for regulating B cell signaling[J]. Immunity, 2000, 13(5): 621-631. DOI: 10.1016/s1074-7613(00)00062-5.
    [11]
    KUKLINA EM, NEKRASOVA IV. New aspects of the Seam4D-dependent control of lymphocyte activation[J]. Dokl Biol Sci, 2017, 473(1): 84-88. DOI: 10.1134/S0012496617020028.
    [12]
    MALEKI KT, CORNILLET M, BJÖRKSTRÖM NK. Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases[J]. Clin Immunol, 2016, 163: 52-59. DOI: 10.1016/j.clim.2015.12.012.
    [13]
    HE Y, GUO Y, FAN C, et al. Interferon-α-Enhanced CD100/Plexin-B1/B2 interactions promote natural killer cell functions in patients with chronic hepatitis C virus infection[J]. Front Immunol, 2017, 8: 1435. DOI: 10.3389/fimmu.2017.01435.
    [14]
    CH'NG ES, KUMANOGOH A. Roles of Sema4D and Plexin-B1 in tumor progression[J]. Mol Cancer, 2010, 9: 251. DOI: 10.1186/1476-4598-9-251.
    [15]
    TANG GJ, YOU J, LIU HE, et al. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. J Clin Hepatol, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035.

    唐光俊, 游晶, 刘怀鄂, 等. 辅助性T淋巴细胞17/调节性T淋巴细胞比值失衡在HBV相关肝脏疾病进展中的作用[J]. 临床肝胆病杂志, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035.
    [16]
    ASABE S, WIELAND SF, CHATTOPADHYAY PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection[J]. J Virol, 2009, 83(19): 9652-9662. DOI: 10.1128/JVI.00867-09.
    [17]
    YANG PL, ALTHAGE A, CHUNG J, et al. Immune effectors required for hepatitis B virus clearance[J]. Proc Natl Acad Sci U S A, 2010, 107(2): 798-802. DOI: 10.1073/pnas.0913498107.
    [18]
    WANG Y, XU N, LI XX. An analysis of T lymphocyte level inhepatitis B virus infected patients with different degree of inflammatory gastric mucosal lessons[J]. Chin Hepatol, 2021, 26(11): 1236-1239. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.014.

    王炎, 许娜, 李小心. 乙型肝炎患者的T淋巴细胞水平与胃黏膜炎性病变程度[J]. 肝脏, 2021, 26(11): 1236-1239. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.014.
    [19]
    LIU X, HE L, HAN J, et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer[J]. PLoS One, 2017, 12(2): e0170605. DOI: 10.1371/journal.pone.0170605.
    [20]
    CHU YL, GU HL, LAN J, et al. Biomarkers in peripheral blood T-lymphocyte subsets of patients with chronic hepatitis B and its advanced liver diseases[J]. Pract Prey Med, 2016, 23(7): 873-876. DOI: 10.3969/j.issn.1006-3110.2016.07.034.

    楚玉兰, 顾洪立, 兰继, 等. 慢性乙型肝炎及后期肝病患者外周血T淋巴细胞亚群标志的研究[J]. 实用预防医学, 2016, 23(7): 873-876. DOI: 10.3969/j.issn.1006-3110.2016.07.034.
    [21]
    YANG S, WANG L, PAN W, et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol, 2019, 71(4): 685-698. DOI: 10.1016/j.jhep.2019.05.013.
    [22]
    LIU HJ. The expression of soluble Sema4D in the serum of patients with chronic hepatitis B and its clinical significance[D]. Lanzhou: Gansu University of Traditional Chinese Medicine, 2021. DOI: 10.27026/d.cnki.ggszc.2021.000017.

    刘亨晶. 可溶性Sema4D在慢性乙型肝炎患者血清中的表达及其临床意义[D]. 兰州: 甘肃中医药大学, 2021. DOI: 10.27026/d.cnki.ggszc.2021.000017.
    [23]
    WANG GL, WANG ZH, ZHANG XL, et al. The relationship between serum Sema4D, BMP-4, AFU and clinicopathological characteristics and prognostic survival of patients with hepatitis B related liver cancer[J]. Chin J Surg Oncol, 2021, 13(2): 185-190. DOI: 10.3969/j.issn.1674-4136.2021.02.017.

    王桂玲, 王治海, 张香玲, 等. 血清Sema4D、BMP-4、AFU与乙肝相关肝癌患者临床病理特征及预后的关系[J]. 中国肿瘤外科杂志, 2021, 13(2): 185-190. DOI: 10.3969/j.issn.1674-4136.2021.02.017.
    [24]
    ZHAO HY, YANG D, HONG W, et al. Analysis of HBV-DNA level, HBV-M and lymphocyte subtype characteristics in patients with chronic hepatitis B and hepatitis B cirrhosis[J]. Guangdong Med J, 2019, 40(3): 432-435. DOI: 10.13820/j.cnki.gdyx.20183783.

    赵海燕, 杨东, 洪伟, 等. 慢性乙型肝炎、乙肝肝硬化患者中HBV-DNA水平、HBV-M、淋巴细胞亚型特点分析[J]. 广东医学, 2019, 40(3): 432-435. DOI: 10.13820/j.cnki.gdyx.20183783.
    [25]
    ERIKSSON EM, MILUSH JM, HO EL, et al. Expansion of CD8+ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity[J]. Blood, 2012, 119(3): 745-755. DOI: 10.1182/blood-2010-12-324848.
    [26]
    LIU ZM, ZOU C. The correlation of FibroScan parameter with serum inflammationindexes, collagen metabolism indexes and fibrosis indexes inpatients with hepatitis B cirrhosis[J]. J Hanan Med Coll, 2018, 24(5): 597-600. DOI: 10.13210/j.cnki.jhmu.20180227.006.

    刘祖明, 邹灿. 乙肝肝硬化患者FibroScan参数与血清炎症指标、胶原代谢指标及纤维化指标的相关性[J]. 海南医学院学报, 2018, 24(5): 597-600. DOI: 10.13210/j.cnki.jhmu.20180227.006.
    [27]
    WANG L, LIAO Y, YANG R, et al. Sja-miR-71a in Schistosome egg-derived extracellular vesicles suppresses liver fibrosis caused by schistosomiasis via targeting semaphorin 4D[J]. J Extracell Vesicles, 2020, 9(1): 1785738. DOI: 10.1080/20013078.2020.1785738.
    [28]
    LE HW, WANG YY. Change of blood coagulation, fibrinolysis and danti-coagulation indexes during the progress of chronic hepatitis B[J]. Lab Med Clin, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010.

    乐华文, 王依屹. 凝血、纤溶和抗凝指标在慢性乙型肝炎病情进展中的变化规律[J]. 检验医学与临床, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010.
    [29]
    LUO ZF, HE YM, XU Y. The role and mechanism of CD100 in the secretion of IgA by B lymphocytes in the pathogenesis of henoch-schönlein purpura[J]. Sichuan Med J, 2020, 41(7): 701-706. DOI: 10.16252/j.cnki.issn1004-0501-2020.07.008.

    罗卓夫, 何渊民, 许飏. CD100在参与过敏性紫癜发病中B淋巴细胞分泌IgA的作用及机制初探[J]. 四川医学, 2020, 41(7): 701-706. DOI: 10.16252/j.cnki.issn1004-0501-2020.07.008.
    [30]
    MOVILA A, MAWARDI H, NISHIMURA K, et al. Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ)[J]. Biochem Biophys Res Commun, 2016, 480(1): 42-47. DOI: 10.1016/j.bbrc.2016.10.012.
    [31]
    WANG Y, ZHU YZ, CHONG Y, et al. Research of the relationship between serum HBV-DNA content and ALT level in hepatitis B patients[J]. Prog Mod Biomed, 2014, 14(29): 5735-5737, 5746. DOI: 10.13241/j.cnki.pmb.2014.29.035.

    王元, 朱亚洲, 种莹, 等. 乙肝患者血清的HBV-DNA含量与ALT水平的关系研究[J]. 现代生物医学进展, 2014, 14(29): 5735-5737, 5746. DOI: 10.13241/j.cnki.pmb.2014.29.035.
    [32]
    HE XQ, SONG XM, GUO JJ. A review of hepatitis B virus infection and hepatitis B-related hepatitis cancer disease development[J]. Science Consultation (Science and Technology Management), 2018(14): 53-55. DOI: 10.3969/j.issn.1671-4822.2018.14.037.

    贺小琴, 宋孝美, 郭进军. 乙肝病毒感染与乙肝相关肝癌疾病发展的综述[J]. 科学咨询(科技·管理), 2018(14): 53-55. DOI: 10.3969/j.issn.1671-4822.2018.14.037.
    [33]
    CHEN JD, ZHAI RR, LIU C, et al. Study on the correlation between serum hepatitis B B virus core antibody and alanine aminotransferase, hepatitis B virus nucleic acid copy number in patients with chronic hepatitis B cirrhosis[J]. Clin J Med Offic, 2021, 49(8): 906-907. DOI: 10.16680/j.1671-3826.2021.08.18.

    陈家东, 翟荣荣, 刘灿, 等. 慢性乙肝肝硬化患者血清乙肝病毒核心抗体定量与谷丙转氨酶、乙肝病毒核酸拷贝数相关性研究[J]. 临床军医杂志, 2021, 49(8): 906-907. DOI: 10.16680/j.1671-3826.2021.08.18.
    [34]
    HE Y, LI BJ, ZHOU Y, et al. Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment[J]. Chin J Cell Mol Immunol, 2014, 30(8): 856-860. DOI: 10.13423/j.cnki.cjcmi.006983.

    何瑜, 李冰洁, 周云, 等. 慢性丙型病毒性肝炎患者抗病毒治疗前后自然杀伤细胞CD100表达水平变化[J]. 细胞与分子免疫学杂志, 2014, 30(8): 856-860. DOI: 10.13423/j.cnki.cjcmi.006983.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (279) PDF downloads(37) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return